<p>Donor lymphocyte infusion (DLI) is an established mode of adoptive cellular therapy for treatment of relapsed disease after allogeneic hematopoietic stem cell transplantation (HSCT). For patients with acute myeloid leukemia (AML), the response rate to DLI is only 20%. Here we use next generation sequencing technologies to understand the transcriptomic and immunologic features associated with response or resistance to therapy. </p>

Elucidating Mechanisms of the Graft versus Leukemia Effect of    Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia

Leukemia, Myeloid, Acute study with OTHER, WXS data on dbGaP (25 participants)

Elucidating Mechanisms of the Graft versus Leukemia Effect of Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia

Description

Applying For Access

Summary